Physician-Scientist.
Principal Investigator, Shenoy Lab, Albert Einstein Cancer Center. Attending Physician, Medical Oncology, Montefiore (GU Oncology, with a focus on kidney cancer).
Interests
Basic/ Translational/ Clinical Cancer research: Interactions between driver pathways, metabolism, epigenetics and immune evasion; Cancer biology; DNA methylation in cancer; Experimental Therapeutics; Early phase clinical trials
Clinical Medicine: Clinical Oncology (Genitourinary malignancies); Clinical Internal Medicine
Teaching (medical students/ residents/ clinical and post-doctoral fellows)
Ethics in Academia
A. Understanding and targeting epigenetic dysregulation, aberrant metabolism, and immune evasion in cancer
- Aggarwal RK, Zou Y, Luchtel RA, Pradhan K, Ashai N, Ramachandra N, Albanese J, Yang J, Wang X, Aluri S, Gordon S, Machha V, Tischer A, Aboumohamed A, Gartrell B, Hafizi S, Pullman J, Shenoy N*. Functional succinate dehydrogenase deficiency and loss of ascorbic acid transporter SLC23A1 are pathognomonic adverse features of clear cell renal cancer. Preprint at Biorxiv (https://www.biorxiv.org/content/10.1101/2020.07.05.188433v2). *corresponding
- Luchtel RA, Bhagat T, Pradhan K, Jacobs WR, Levine M, Verma A, Shenoy N*. High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model. Proc Natl Acad Sci U S A. 2020 Jan 7. pii: 201908158. doi: 10.1073/pnas.1908158117. [Epub ahead of print] PMID: 31911474. *corresponding
- Shenoy N*, Bhagat TD, Cheville JC, Lohse C, Bhattacharyya S, et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. J Clin Invest 2019 Mar 4;130:1612-1625. PMID: 30702441. *co-corresponding (JCI Editor's pick, April 2019 issue)
- Shenoy N*, Creagan E, Witzig T, Levine M. Ascorbic acid in cancer treatment: Let the phoenix fly. Cancer Cell. 2018 Nov 12;34(5):700-706.(Review) PMID: 30174242. *co-corresponding
- Shenoy N*, Bhagat T, Nieves E, Stenson M, Lawson J, et al. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J. 2017 Jul 21;7(7): e587. PMID: 28731456. *co-corresponding
- Shenoy N*. Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid. Mol Cell Oncol. 3 April 2019. PMID: 31131312. *corresponding
B. Kidney cancer translational research
- Shenoy N*, Bhagat TD, Cheville JC, Lohse C, Bhattacharyya S, et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. J Clin Invest 2019 Jan 31. pii: 98747. doi: 10.1172/JCI98747. PMID: 30702441. *co-corresponding
- Shenoy N*. HIF1α is not a target of 14q deletion in clear cell renal cancer. Sci Rep 2020 Oct 19;10(1):17642. PMID: 33077781. *corresponding
- Wang X, Lopez R, Luchtel RA, Hafizi S, Gartrell B, Shenoy N*. Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int 2020 Sep 17;S0085-2538(20)31078-4. *corresponding
- Shenoy N*, Pagliaro L: Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol 2016 Sep;27(9):1685-95. PMID: 27329246. *corresponding
- Shenoy N*, Vallumsetla N, Galeas JN, Shrivastava M, Hu C, et al. Role of DNA Methylation in Renal Cell Carcinoma. J Hematol Oncol 2015 Jul 22;8:88. PMID: 26198328. *co-corresponding
- Shenoy N*, Shrivastava M, Sukrithan V, Papaspyridi D, Darbinyan K. The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. J Cancer Ther 2015 Jun;6 (06): 511-521. *corresponding
- Hu CY, Mohtat D, Yu YA, Ko Y, Shenoy N, et al. Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival. Clin Can Res 2014 Aug 15;20(16):4349-60. PMID: 24916699.
- Shenoy N* et al. Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? Clin Genitourin Cancer. 2018 Jun 28. PMID: 30077464. *co-corresponding
- Shenoy N*, Pagliaro L. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Eur Urol. 2018 Feb;73(2):304-305 Words of Wisdom section. PMID: 29102314. *corresponding
- Shenoy N*. Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid. Mol Cell Oncol. 3 April 2019. PMID: 31131312. *corresponding
- Aggarwal RK, Zou Y, Luchtel RA, Pradhan K, Ashai N, Ramachandra N, Albanese J, Yang J, Wang X, Aluri S, Gordon S, Machha V, Tischer A, Aboumohamed A, Gartrell B, Hafizi S, Pullman J, Shenoy N*. Functional succinate dehydrogenase deficiency and loss of ascorbic acid transporter SLC23A1 are pathognomonic adverse features of clear cell renal cancer. Preprint at Biorxiv (https://www.biorxiv.org/content/10.1101/2020.07.05.188433v2). *corresponding
C. Ethics in Academia
- Shenoy N*. Professional Ethics in Academia: defining the categories of behavior spectrum in matters of unethical conduct. International Journal of Ethics Education (2019), official journal of the International Association for Education in Ethics- a UNESCO initiative. https://doi.org/10.1007/s40889-019-00071-1 *corresponding
Other publications listed below
Active Clinical Trial Protocols:
1. Randomized phase II trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Azacytidine in Higher-Risk Myelodysplastic Syndromes
Role: PI and wrote the protocol. Status: pending regulatory approvals
2. Randomized phase II trial of Intravenous Ascorbic acid as an adjunct to pazopanib for metastatic and unresectable clear cell renal cell carcinoma (ccRCC): A study of Academic and Community Cancer Research United (ACCRU) GU1703.
Role: Co-PI and wrote the protocol. Clinicaltrials.gov Identifier: NCT03334409. Status: open to accrual
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.TPS679
3. Phase II Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma
Role: Co-PI and wrote the protocol. Clinicaltrials.gov Identifier: NCT03418038. Status: open to accrual
Medical Education and Training:
Medical school: Bangalore Medical College and Research Institute, India
Residency: Internal Medicine, Albert Einstein College of Medicine/ Jacobi Medical Center, NY, USA
Chief Residency: Internal Medicine, Albert Einstein College of Medicine/ Jacobi Medical Center, NY, USA
Fellowship: Hematology and Oncology, Mayo Clinic Rochester, MN, USA
Master of Science (Clinical Research): Drexel University College of Medicine, PA, USA
Doctor of Philosophy (PhD): Dept of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK
Thesis: Understanding and targeting epigenetic dysregulation, aberrant metabolism, and immune evasion in cancer with ascorbic acid
Viva dissertation defense examiners’ institutions: University of Birmingham (external 1), University of Wolverhampton (external 2), University of Portsmouth (internal)
Select Honors/ Awards:
American Cancer Society Research Scholar Grant award
American Society for Clinical Investigation Young Physician Scientist award
Selection as a Paul Calabresi K12 Scholar at Einstein/ Montefiore (highest score). Transitioned to independent investigator prior to formal enrollment in the Calabresi program.
American Society of Hematology Research Award for Fellows
National Cancer Institute SPORE Development Research Project Award
Mayo Clinic William H.J. Summerskill Award (highest fellowship honor, Mayo Clinic School of Graduate Medical Education)
Winner, Mayo Clinic Young Investigators Research Symposium
American Federation for Medical Research Henry Christian Award
Leo. M. Davidoff society of the Albert Einstein College of Medicine Recognition Award for teaching excellence
Gold medal, Medicine, Bangalore Medical College & Research Institute
American Board Certifications:
Internal Medicine; Medical Oncology; Hematology